GALR2, galanin receptor 2, 8811

N. diseases: 41; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.010 Biomarker group BEFREE GALR2 is a potentially significant therapeutic target and prognostic factor for this cancer type. 24122450 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 PosttranslationalModification group BEFREE GALR2 methylation found in 31 of 100 (31.0%) tumor specimens was significantly correlated with the methylation status of both GALR1 and Galanin. 24122450 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE Additionally, galanin had no effect on the hemoglobin content of tumors derived from cells lacking GALR2. 29123986 2017
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.500 Biomarker disease CTD_human Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. 27940914 2016
CUI: C0011574
Disease: Involutional Depression
Involutional Depression 		0.300 Biomarker disease CTD_human Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. 27940914 2016
CUI: C1571983
Disease: Involutional paraphrenia
Involutional paraphrenia 		0.300 Biomarker disease CTD_human Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. 27940914 2016
CUI: C1571984
Disease: Psychosis, Involutional
Psychosis, Involutional 		0.300 Biomarker disease CTD_human Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide. 27940914 2016
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.020 Biomarker disease BEFREE Although this homozygous SNV was rare in our MS cohort (1:262 cases), our findings raise the potential importance of impaired neuroregenerative pathways in the pathogenesis of MS, warrant future studies into the relevance of the GAL/GALR2 axis in MS and further suggest the activation of GALR2 as a potential therapeutic route for this disease. 30131588 2019
CUI: C0494491
Disease: Mononeuropathies
Mononeuropathies 		0.010 AlteredExpression group BEFREE And there may be plastic changes in the expression of galanin and galanin receptor 2 in rats with mononeuropathy, as well as in the galanin-induced antinociception. 28378856 2017
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.010 Biomarker disease BEFREE But no literature are available regarding the effect of galanin receptor 2 (GALR2) on insulin resistance in skeletal muscle of type 2 diabetes. 29183756 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE Expression of GalR1 was relatively increased in most, whereas GalR2 was decreased in some tumors. 22889491 2012
CUI: C2349952
Disease: Oropharyngeal Carcinoma
Oropharyngeal Carcinoma 		0.010 Biomarker disease BEFREE Furthermore, methylation of GAL, GALR1, or GALR2 exhibited the highest association with poor survival (log-rank test, P = 0.018) in patients with HPV-negative oropharyngeal cancers. 27685843 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.020 Biomarker disease BEFREE Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. 14592962 2004
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.020 Biomarker disease BEFREE Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. 14592962 2004
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.020 Biomarker disease BEFREE Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. 14592962 2004
CUI: C0011581
Disease: Depressive disorder
Depressive disorder 		0.320 GeneticVariation disease BEFREE Here we report that variants in genes for galanin (GAL) and its receptors (GALR1, GALR2, GALR3), despite their disparate genomic loci, conferred increased risk of depression and anxiety in people who experienced childhood adversity or recent negative life events in a European white population cohort totaling 2,361 from Manchester, United Kingdom and Budapest, Hungary. 24706871 2014
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.020 GeneticVariation disease BEFREE Here we report that variants in genes for galanin (GAL) and its receptors (GALR1, GALR2, GALR3), despite their disparate genomic loci, conferred increased risk of depression and anxiety in people who experienced childhood adversity or recent negative life events in a European white population cohort totaling 2,361 from Manchester, United Kingdom and Budapest, Hungary. 24706871 2014
CUI: C0344315
Disease: Depressed mood
Depressed mood 		0.020 GeneticVariation phenotype BEFREE Here we report that variants in genes for galanin (GAL) and its receptors (GALR1, GALR2, GALR3), despite their disparate genomic loci, conferred increased risk of depression and anxiety in people who experienced childhood adversity or recent negative life events in a European white population cohort totaling 2,361 from Manchester, United Kingdom and Budapest, Hungary. 24706871 2014
CUI: C0003467
Disease: Anxiety
Anxiety 		0.040 Biomarker disease BEFREE Here we report that variants in genes for galanin (GAL) and its receptors (GALR1, GALR2, GALR3), despite their disparate genomic loci, conferred increased risk of depression and anxiety in people who experienced childhood adversity or recent negative life events in a European white population cohort totaling 2,361 from Manchester, United Kingdom and Budapest, Hungary. 24706871 2014
CUI: C0003469
Disease: Anxiety Disorders
Anxiety Disorders 		0.040 Biomarker group BEFREE Here we report that variants in genes for galanin (GAL) and its receptors (GALR1, GALR2, GALR3), despite their disparate genomic loci, conferred increased risk of depression and anxiety in people who experienced childhood adversity or recent negative life events in a European white population cohort totaling 2,361 from Manchester, United Kingdom and Budapest, Hungary. 24706871 2014
CUI: C1519670
Disease: Tumor Angiogenesis
Tumor Angiogenesis 		0.010 Biomarker phenotype BEFREE Here, we report that GALR2 stimulates tumor angiogenesis in SCCHN via p38-mediated inhibition of TTP with resultant enhanced cytokine secretion. 24568968 2014
CUI: C0031511
Disease: Pheochromocytoma
Pheochromocytoma 		0.020 Biomarker disease LHGDN In addition, p21(cip1) levels were up-regulated in galanin-exposed PC12 cells and down-regulated in galanin-exposed GalR2-transfected cells. 18272487 2008
CUI: C1168401
Disease: Squamous cell carcinoma of the head and neck
Squamous cell carcinoma of the head and neck 		0.050 AlteredExpression disease BEFREE In conclusion, GALR2 expression in the presence of galanin exerts antitumor effects via cell cycle arrest and apoptotic pathways, and reactivation of these pathways may have therapeutic benefits in HNSCC. 25017118 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE In head and neck squamous carcinoma cells (HNSCC) with silenced GALR1 and GALR2, we showed that reexpressed GALR1 suppresses tumor cell proliferation via Erk1/2-mediated effects on cdk inhibitors and cyclin D1. 19276245 2009
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.080 Biomarker group BEFREE In the present study, it was demonstrated that the re‑expression of GALR1 in GALR1 and GALR2‑negative HNSCC cells suppresses tumor cell proliferation. 25017118 2014